{"product_id":"daiichisankyo-five-forces-analysis","title":"Daiichi Sankyo Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDaiichi Sankyo faces intense rivalry from Big Pharma and biotech rivals, while patent lifecycles and regulatory hurdles shape supplier and buyer power. Threats from generics and new entrants are mitigated by strong R\u0026amp;D and strategic partnerships, but substitutes and pricing pressure remain material. This brief snapshot highlights key forces but omits force-by-force ratings and visuals. Unlock the full Porter's Five Forces Analysis for a consultant-grade, data-driven breakdown to inform strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty API and payload concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSophisticated oncology assets depend on complex active ingredients, linkers and cytotoxic payloads sourced from a limited set of qualified suppliers, concentrating bargaining power. Scarcity and high switching costs give suppliers leverage over pricing and lead times; qualification and regulatory filings for dual-sourcing typically take 6–12 months. Any disruption can ripple through clinical and commercial chains, causing delays of months to quarters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and sterile manufacturing capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal capacity for high-potency and sterile biologics tightened in 2024, with CDMO biologics utilization above 85%, boosting supplier bargaining power. Slot allocation and tech-transfer timelines of 12–24 months can dictate Daiichi Sankyo launch cadence and prioritization. Long-term capacity reservations often lock \u0026gt;30% of annual capacity, reducing flexibility and raising fixed costs. Suppliers have passed through manufacturing input and compliance cost inflation of roughly 6% YoY in 2023–24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary equipment and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary single-use systems, chromatography resins and specialized conjugation equipment are supplied by few vendors, creating high supplier power for Daiichi Sankyo; the single-use systems market was estimated near $5 billion in 2024, underscoring supplier concentration. Qualification and GMP documentation lock in suppliers and lead-time volatility (often several weeks to months) forces higher safety stocks. Volume commitments and strategic alliances can mitigate but not eliminate dependence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData, software, and trial services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eData, software and trial services (CROs, EDC platforms, real-world data providers) are critical to Daiichi Sankyo development timelines; the CRO market ~USD 60B in 2024, giving vendors leverage. High mid-trial switching costs raise vendor power; premium providers command ~20–30% higher fees for speed, global reach and quality. Multi-vendor strategies reduce single-vendor risk but add oversight complexity and ~10–20% higher management cost.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCRO market: ~USD 60B (2024)\u003c\/li\u003e\n\u003cli\u003ePremium fee uplift: ~20–30%\u003c\/li\u003e\n\u003cli\u003eMulti-vendor oversight cost: ~10–20%\u003c\/li\u003e\n\u003cli\u003eHigh mid-trial switching cost increases vendor bargaining power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality compliance constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and quality deviations in active pharmaceutical ingredient or finished-dose suppliers can trigger batch rejections and regulatory scrutiny, with supplier remediation and requalification commonly taking 6–18 months, prolonging dependence on incumbents. Stringent audit and qualification requirements shrink the eligible supplier pool, increasing supplier bargaining leverage and raising supply-chain risk for Daiichi Sankyo.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBatch rejections → regulatory inspections\u003c\/li\u003e\n\u003cli\u003eQualification lead time: 6–18 months\u003c\/li\u003e\n\u003cli\u003eSmaller qualified pool → higher supplier leverage\u003c\/li\u003e\n\u003cli\u003eRemediation prolongs incumbent dependence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated CDMO supply (\u003cstrong\u003e\u0026gt;85%\u003c\/strong\u003e utilization) and scarce HPAPI vendors drive pricing, lead-time risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high leverage over Daiichi Sankyo due to concentrated CDMO capacity (utilization \u0026gt;85% in 2024), scarce HPAPI\/linker vendors and long qualification times (6–18 months), driving pricing and lead-time risk. Key markets: CRO ~USD60B (2024), single-use systems ~USD5B (2024); premium vendors charge ~20–30% uplift. Capacity reservations often lock \u0026gt;30% annual slots, reducing flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO utilization\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO market\u003c\/td\u003e\n\u003ctd\u003e~USD60B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-use market\u003c\/td\u003e\n\u003ctd\u003e~USD5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium fee uplift\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualification lead time\u003c\/td\u003e\n\u003ctd\u003e6–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Daiichi Sankyo, analyzing its position within its competitive landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Daiichi Sankyo—instantly visualize competitive pressures with a spider chart and customizable intensity levels, ready to drop into pitch decks or executive reports to simplify strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational health systems and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingle-payer systems and HTA bodies (eg NICE, ICER) exert strong price and access pressure, applying cost-effectiveness thresholds—NICE ~£20,000–30,000\/QALY and ICER commonly $100,000–150,000\/QALY in 2024—that shape reimbursement decisions.\u003c\/p\u003e\n\u003cp\u003eBudget-impact tests and national price negotiations can delay or restrict market entry, compressing peak sales and time-to-revenue.\u003c\/p\u003e\n\u003cp\u003eRobust outcomes evidence and pharmacoeconomic dossiers are therefore decisive negotiating tools for Daiichi Sankyo in securing favorable access and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBMs and formulary gatekeepers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and hospital formularies control access via tiers and prior authorizations in key markets. Top 3 PBMs manage roughly 80% of US prescription claims (2024) and leverage therapeutic alternatives to extract rebates typically in the 20–40% range. Limited differentiation for Daiichi Sankyo assets intensifies discount demands. Alignment with companion diagnostics can increase chances of preferred placement by about 25% (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologists and treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialist prescribers prioritize efficacy, safety and ease of use, with guideline endorsement and KOL support materially increasing uptake—guideline inclusion commonly boosts prescribing by \u0026gt;30% in oncology. Administration route shifts economics: hospital IV infusions are often 2–3x costlier than outpatient\/oral alternatives, shaping site-of-care decisions. Robust education and 2024 real-world evidence accelerate adoption curves and reduce demand elasticity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and advocacy groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient and advocacy groups shape policy, access programs and trial recruitment by lobbying regulators and sponsoring registries, often accelerating formulary review and enrollment in rare-disease trials; in high unmet-need areas patients show greater risk tolerance which can reduce price sensitivity while co-pay burdens remain a key determinant of adherence and persistence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient influence: affects policy, access, trials\u003c\/li\u003e\n\u003cli\u003eHigh unmet need: raises risk tolerance, lowers price sensitivity\u003c\/li\u003e\n\u003cli\u003eCo-pay burden: drives nonadherence\/persistence issues\u003c\/li\u003e\n\u003cli\u003eSupport services: increase perceived value and uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTendering and international reference pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTendering and cross-country reference pricing amplify discounts for Daiichi Sankyo as group purchasing in hospitals (GPOs cover ~76% of US hospital drug spend) and international reference pricing (used in 20+ countries) spread lower net prices; competitive tenders intensify for hospital-administered therapies and parallel trade risks erode price consistency across EU markets. Managed entry agreements increasingly trade price for real-world evidence commitments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGPO exposure ~76%\u003c\/li\u003e\n\u003cli\u003eReference pricing: 20+ countries\u003c\/li\u003e\n\u003cli\u003eHigh tender competition in hospital-administered drugs\u003c\/li\u003e\n\u003cli\u003eParallel trade pressures net price\u003c\/li\u003e\n\u003cli\u003eMEAs link discounts to evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs and GPOs squeeze drug prices while outcomes-based access expands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSingle-payer HTA (NICE £20–30k\/QALY; ICER $100–150k\/QALY in 2024) and national negotiators exert strong price\/access pressure.\u003c\/p\u003e\n\u003cp\u003eTop 3 PBMs cover ~80% of US claims (2024), extracting 20–40% rebates; GPOs account for ~76% of US hospital drug spend, intensifying tender discounts.\u003c\/p\u003e\n\u003cp\u003ePatient groups, guideline endorsement and MEAs (20+ countries with reference pricing) push outcomes-linked pricing and conditional access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNICE threshold\u003c\/td\u003e\n\u003ctd\u003e£20–30k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICER range\u003c\/td\u003e\n\u003ctd\u003e$100–150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop3 PBM share (US)\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM rebates\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO hospital spend\u003c\/td\u003e\n\u003ctd\u003e~76%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReference pricing countries\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eDaiichi Sankyo Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Daiichi Sankyo Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or samples. The file is professionally formatted, complete, and ready for download and use the moment you buy. No mockups or edits required; this is the final deliverable you’ll get instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eivalry Among Competitors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense oncology competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntense oncology competition sees Roche, Merck, BMS, Pfizer and AstraZeneca targeting overlapping indications, with the global oncology market \u0026gt;$200B in 2024. Speed to first- or best-in-class determines market share as head-to-head and cross-trial comparisons fuel marketing battles. Line-extension races crowd later lines of therapy, compressing pricing and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid innovation and lifecycle pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShort innovation cycles erode exclusivity as competitors deploy new mechanisms, combos and biomarkers; in oncology this is acute—Daiichi Sankyo had over 100 ongoing Enhertu trials in 2024 to protect label breadth. Post-approval studies are essential to defend indications and reimbursement, while lifecycle management must balance incremental efficacy, safety signals and patient convenience to sustain peak sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships and co-promotion dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliances expand Daiichi Sankyo’s reach but introduce shared economics and strategic complexity, especially in oncology where the global market exceeded $200 billion in 2024. Co-promote partners like AstraZeneca may still compete in adjacent indications, raising clash risks. Milestones and profit splits focus management on flawless execution. Global coordination becomes a competitive necessity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and market access battles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRival discounting and outcomes contracts compress Daiichi Sankyo's net price realization, with payers in 2024 increasingly favoring value-based deals that shift revenue variability to performance.\u003c\/p\u003e\n\u003cp\u003eHTA judgments in 2024 frequently redirected volume toward established comparators, materially affecting launch uptake in core oncology and cardiology markets.\u003c\/p\u003e\n\u003cp\u003eReal-world effectiveness and safety signals now move prescriber preference within weeks; access breadth and payer formulary placement often outweigh list price in determining market share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003enet-price pressure: outcomes contracts rising in 2024\u003c\/li\u003e\n\u003cli\u003eHTA-driven share shifts: comparators favored post-HTA\u003c\/li\u003e\n\u003cli\u003eRWE impact: rapid prescriber shifts within weeks\u003c\/li\u003e\n\u003cli\u003eAccess\u0026gt;list-price: formulary breadth key to volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal footprint and supply reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitors with robust manufacturing and distribution capture outsized share during demand surges, critical in a global pharma market valued at about 1.6 trillion USD in 2024. Avoiding stockouts preserves brand trust and launch momentum; regional localization and rapid regulatory compliance deliver competitive agility across markets. Pharmacovigilance metrics and recall rates materially drive reputational rivalry and prescribing confidence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing scale advantage\u003c\/li\u003e\n\u003cli\u003eStockout avoidance = brand retention\u003c\/li\u003e\n\u003cli\u003eLocalization \u0026amp; compliance agility\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance performance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology rivalry (\u0026gt;\u003cstrong\u003e$200B\u003c\/strong\u003e) accelerates launches, crowds lines and compresses pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntense oncology rivalry (global oncology \u0026gt;$200B in 2024) drives speed-to-first\/best-in-class, line-extension crowding and compressed pricing; Daiichi Sankyo ran \u0026gt;100 Enhertu trials in 2024 to protect label. Outcomes contracts and HTA decisions in 2024 shifted net-price realization and launch uptake rapidly.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma market\u003c\/td\u003e\n\u003ctd\u003e$1.6T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eSubstitutes Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics and biosimilars on loss of exclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent expiries trigger rapid price erosion and share loss, with generic entry often cutting prices by up to 80% in major markets and wiping out blockbuster margins within 12–24 months. Biosimilars have eroded biologic franchises—e.g., post-2023 anti-TNF biosimilars reached \u0026gt;60% volume share in parts of Europe—especially in hospital formularies. Daiichi Sankyo leans on differentiation, new indications and lifecycle patents, while contracting and tendering can slow but not fully prevent substitution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative modalities and regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunotherapies, cell and gene therapies, and radiopharmaceuticals increasingly displace targeted drugs, with CAR-Ts showing overall response rates of roughly 40–80% in hematologic cancers and immuno-oncology representing about half of late-stage oncology pipelines by 2024. Oral agents gain share for convenience, with oral formulations comprising roughly 30% of recent oncology approvals through 2019–2024. Combination regimens push many monotherapies to later lines, altering treatment sequencing, infusion-center volumes and drug-cost economics, increasing per-patient treatment costs while shifting revenue toward high-margin, single-dose cell therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-pharmacologic interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgery, radiation, and ablation can obviate or delay systemic drugs in early-stage indications, shifting spend toward one-time procedures. Enhanced screening and prevention — WHO estimates 30–50% of cancers are preventable — lower incident treatment demand. Digital therapeutics and supportive care (FDA-cleared DTx \u0026gt;60 by 2024) can shorten or reduce drug therapy intensity. Clinical guidelines ultimately mediate adoption and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics-driven selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiomarker-driven companion diagnostics can exclude large patient subsets, in some indications reducing eligible populations by up to 80%, shifting demand toward alternative therapies and biosimilars; diagnostic advances favor rival mechanisms and platform competitors. Test availability and 48–72 hour turnaround in 2024 materially influence prescribing; payer coverage variability (CDx market ≈ $7.2B in 2024) shifts therapy mix.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExclusion impact: up to 80%\u003c\/li\u003e\n\u003cli\u003eTurnaround: 48–72 hours\u003c\/li\u003e\n\u003cli\u003eMarket size 2024: ≈ $7.2B\u003c\/li\u003e\n\u003cli\u003ePayer coverage: major determinant of therapy uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic switching due to safety\/tolerability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAdverse events frequently prompt prescribers to switch patients to competitor therapies, with post‑marketing safety signals often accelerating substitution beyond clinical trial findings. Dosing convenience and monitoring burden amplify this effect by making alternatives more attractive. Once patients stabilize on substitutes, patient preference and adherence consolidate market shifts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdverse-event driven switches\u003c\/li\u003e\n\u003cli\u003eReal-world safety accelerates substitution\u003c\/li\u003e\n\u003cli\u003eDosing\/monitoring influence uptake\u003c\/li\u003e\n\u003cli\u003ePatient preference consolidates change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePATENT CLIFFS, GENERICS AND BIOSIMILARS COMPRESS MARGINS AS CAR-T AND CDx RESHAPE ONCOLOGY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatent expiries and generics can cut prices up to 80% within 12–24 months, while biosimilars exceeded 60% volume in parts of Europe by 2024, severely compressing margins. Novel modalities (CAR‑T 40–80% response; immuno‑oncology ~50% of late‑stage pipelines by 2024) and oral\/regimen shifts (oral ≈30% of recent approvals 2019–24) redirect demand. Diagnostics (CDx market ≈ $7.2B in 2024; 48–72h turnaround) and safety\/ convenience drive rapid switching.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics price cut\u003c\/td\u003e\n\u003ctd\u003eup to 80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar volume (EU)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDx market\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR‑T ORR\u003c\/td\u003e\n\u003ctd\u003e40–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral approvals share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003entrants Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D and regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh clinical development costs (Tufts Center estimate ~$2.6B) and long timelines of ~10–12 years, plus stringent FDA\/EMA standards, deter entrants. Manufacturing biologics and ADCs needs specialized facilities and sterile fill\/finish capabilities, raising capex. Ongoing pharmacovigilance and GMP compliance add fixed operational burdens, keeping the threat of new entrants moderate to low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital access and specialized talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVenture funding and active public markets let well-backed biotechs enter oncology niches, but scarce CMC, regulatory, and oncology expertise raises execution risk and timelines; oncology trial screen-failure rates near 70% further constrain capacity. Competition for sites and patients increases trial costs and delays. Partnerships can plug capability gaps but typically share upside and dilute economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP protection and freedom-to-operate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024, dense patent thickets around targets, linkers and payloads held by incumbents sharply limit new entrants into Daiichi Sankyo’s ADC-focused spaces. Complex design-arounds and high litigation risk raise development costs and timelines. Proprietary process-chemistry trade secrets add operational barriers, making cross-licensing often mandatory for freedom-to-operate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform technologies and CDMO ecosystems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePlatform technologies and CDMO ecosystems lower initial capex and enable asset-light entrants; modular platforms accelerate preclinical-to-clinic transitions, shortening timelines. However, scale-up and regulatory quality demands intensify at commercialization, and dependence on shared capacity creates bottleneck risk. Industry reports place the global CDMO market near USD 170 billion in 2024 with high utilization pressures.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower capex: enables asset-light entry\u003c\/li\u003e\n\u003cli\u003eModular platforms: faster IND\/CTA timelines\u003c\/li\u003e\n\u003cli\u003eScale-up risk: higher compliance costs at launch\u003c\/li\u003e\n\u003cli\u003eShared capacity: bottleneck and scheduling risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and commercial scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEstablished payer negotiations, global pricing frameworks and KOL engagement require infrastructure and compelling clinical\/economic data; without them entrants face restrictive formulary access and delayed reimbursement. Global oncology market exceeded $200B in 2024, making commercial scale essential; building specialty salesforces and medical affairs (MSL avg US salary ~$150k in 2024) is costly. Co-commercialization offers faster access but shares economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayer access: HTA and pricing teams needed\u003c\/li\u003e\n\u003cli\u003eCost: specialty reps\/MSLs ~ $150k+ p.a.\u003c\/li\u003e\n\u003cli\u003eScale: oncology market \u0026gt; $200B (2024)\u003c\/li\u003e\n\u003cli\u003eCo-commercialization: quicker access, shared revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e$2.6B\u003c\/strong\u003e R\u0026amp;D, \u003cstrong\u003e10–12 yrs\u003c\/strong\u003e to market — high oncology entry barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh R\u0026amp;D cost (~$2.6B) and 10–12 year timelines, plus strict FDA\/EMA standards and patent thickets, keep entrant threat low. Oncology trial screen-failure ~70% and specialized CMC\/ADC manufacturing raise execution risk. CDMO market ~$170B (2024) and oncology market \u0026gt;$200B (2024) favor incumbents; MSL salary ~ $150k adds commercialization cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg drug R\u0026amp;D cost\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime to market\u003c\/td\u003e\n\u003ctd\u003e10–12 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology screen-fail rate\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003e$170B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSL avg salary (US)\u003c\/td\u003e\n\u003ctd\u003e$150k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097788518748,"sku":"daiichisankyo-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/daiichisankyo-five-forces-analysis.png?v=1781792157","url":"https:\/\/pestel-analysis.com\/products\/daiichisankyo-five-forces-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}